ClinicalTrials.gg
RecruitingNCT07536178LoFUpdated Oct 26, 2026

Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada

An interventional study of Woodsmoke (Lodgepole Pine) exposure and Filtered air exposure in Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University of British Columbia · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 26, 2026Now RecruitingFirst site in Canada+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Asthma by University of British Columbia — 5 open to participants now, 5 under way, none of them phase 3. Asthma · University of British Columbia.

Planned enrollment
12th of 14
24 · median 52
Started
2026
with 1 other
No phase
11 of 20
2 open now
Registered
19th of 20
by date

Among the 20 studies in Asthma by University of British Columbia, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 19th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 20 studies in Asthma by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Asthma by University of British Columbia, or all of them as a file.
02

Study summary

Wildfire smoke (WFS) is the leading climate-related risk in Canada and the main source of harmful air pollution. While short-term breathing problems caused by smoke are well known, there is limited knowledge on how repeated exposure contributes to long-term lung disease. This study is a controlled human exposure to varying concentrations of WFS in a safe setting. By comparing the effects of different concentrations, this research will improve understanding of health impacts, identify who may be most vulnerable to exposures, and explore biological changes that could lead to chronic illness.

Read the detailed description

PURPOSE: To use responses to controlled human exposures to woodsmoke, as a model of wildfire smoke (WFS), to quantify risk of, and add biological plausibility to, the supposition that WFS-related particulate matter with a diameter of 2.5 micrometers or less (PM2.5) contributes to the development of neurological and chronic lung diseases.

Study Exposure Arms:

Arm A: 3 consecutive days with 2h woodsmoke exposures at 35 µg/m3 of PM2.5 Arm B: 3 consecutive days with 2h woodsmoke exposures at 105 µg/m3 of PM2.5 Arm C: 2 consecutive days of Filtered Air (FA), followed by 1 day with a 2h woodsmoke exposure at 315 µg/m3 of PM2.5

HYPOTHESIS, JUSTIFICATIONS, AND OBJECTIVES Aim 1A: Enhance plausibility for, and quantify risk of, WFS contributions to chronic lung disease.

Hypothesis 1A: The investigators will determine mechanisms that plausibly link WFS exposure to the development of chronic disease, by connecting WFS exposures to lung function decline, asthma, chronic obstructive pulmonary disease (COPD), or lung cancer.

To assess the plausibility of linking WFS exposure to Chronic Lung Diseases such as asthma, COPD, and lung cancer.

To evaluate the biological impacts of WFS on the airways.

  • Specifically, what are the effects of exposure concentration, intensity, and time on inflammatory and immunomodulatory responses to WFS exposure?
  • Several biological pathways may link WFS exposures with the development of chronic respiratory diseases such as asthma, COPD, and lung cancer. These include effects of oxidative stress and inflammation on epithelial barrier integrity, which may facilitate contact with immune cells, allergen sensitization, increased infection susceptibility, and tissue remodelling that impairs lung function. Epigenetics, notably DNA methylation (DNAm), is another potential mechanism linking WFS to chronic disease, and the airway microbiome may also contribute through several pathways. However, WFS differs from general urban and traffic-related air pollution (TRAP), so effects of TRAP exposure demonstrated to date cannot be assumed to apply to WFS.

Aim 1B: Use a controlled human exposure study to identify, across different intensities of WFS exposure:

1.1 Neurocognitive changes relevant to the development of chronic neurological diseases 1.2 Temporal patterns of onset and resolution in relevant circulating neuro-inflammatory markers 1.3 Sex, age, and genetics as effect-modifying susceptibility factors for the above phenomena

Hypothesis 1B: The investigators will demonstrate disturbances in the brain default mode network (DMN), and intensity-dependent increases in circulating neuro-inflammatory markers, particularly in older individuals and those with genotypes conferring deficient anti-oxidant metabolism or those conferring risk of dementia.

RESEARCH DESIGN A randomized, double-blinded, crossover-controlled human exposure study.

STATISTICAL ANALYSIS Data will be analysed in R using generalized and linear mixed-effects models. Models will run with exposure as a fixed effect and participant ID as a random effect.

03

Conditions studied

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Lung Cancer

Keywords

  • Wildfire Smoke
  • Chronic Lung Disease
  • Air Pollution
  • Controlled Human Exposure Study
  • Environmental Health
  • PM2.5
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Adults between the ages of 19 to 80 (12 of each biological sex assigned at birth).

Exclusion criteria

Exclusion Criteria:

  1. Current smoker (within six months before screening; potential to confound exposure effects).
  2. History or current diagnosis of any respiratory conditions (including, but not limited to asthma or (COPD), asthma/COPD overlap) or other medical conditions that the study physician determines may impact participant safety.
  3. Any comorbidities or other concerns identified by the study physician which may impact study participation.
  4. For participants of : Current pregnancy, or plans to become pregnant during study enrolment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Arm A) Three repeated exposures to a low air pollution concentration

    Three consecutive days with a 2-hour woodsmoke exposure at 35 µg/m3 of PM2.5 each day.

    Other: Woodsmoke (Lodgepole Pine) exposure

  • Experimental
    Arm B) Three repeated exposures to a moderate air pollution concentration

    Three consecutive days with a 2-hour woodsmoke exposure at 105 µg/m3 of PM2.5 each day.

    Other: Woodsmoke (Lodgepole Pine) exposure

  • Experimental
    Arm C) Single exposure to a higher air pollution concentration

    Two consecutive days of 2-hour filtered air exposures, followed by 1 day with a 2-hour woodsmoke exposure at 315 µg/m3 of PM2.5.

    Other: Woodsmoke (Lodgepole Pine) exposure · Other: Filtered air exposure

Interventions

  • OtherWoodsmoke (Lodgepole Pine) exposure

    Woodsmoke will be freshly generated using a furnace tube burning dried, ground lodgepole pine (Pinus contorta) to achieve the nominal PM2.5 (particulate matter with an aerodynamic diameter of less than or equal to 2.5 micrometres) concentrations specified for each study arm.

  • OtherFiltered air exposure

    Exposures to HEPA filtered air, as a control.

06

What researchers measure

Primary outcomes

  1. Effects of PM2.5 exposures and concentration on exhaled nitric oxide.

    Measurement of fractional exhaled nitric oxide (FeNO).

    Time frame: Comparison of the different arms over the span of 4 months.

  2. Effects of PM2.5 exposures and concentration on Cambridge Neuropsychological Test Automated Battery (CANTAB)

    Computational testing using CANTAB to determine e.g. 5-choice reaction time and percent correct all delays.

    Time frame: Comparison of the different arms over the span of 4 months.

Secondary outcomes

  1. Effects of PM2.5 exposures and concentration on sputum cell numbers.

    Differentially count sputum cells.

    Time frame: Comparison of the different arms over the span of 4 months.

  2. Effects of PM2.5 exposures and concentration on brain functional connectivity.

    Resting-state functional MRI (rs-fMRI) will assess functional connectivity within the default mode network (DMN) using a seed-based approach. Preprocessing will follow established neuroimaging methods. Functional connectivity will be determined as temporal correlations between blood-oxygen-level-dependent (BOLD) signal time series from a posterior cingulate cortex seed and DMN regions, using group-level statistical models.

    Time frame: Comparison of the different arms over the span of 4 months.

  3. Effects of PM2.5 exposures and concentration on oxidative stress.

    Assessment of oxidative stress using H2DCFDA.

    Time frame: Comparison of the different arms over the span of 4 months.

  4. Effects of PM2.5 exposures and concentration on lung inflammatory markers.

    An inflammation matrix will be generated, including data from RNA and protein inflammatory markers (e.g. interleukins (IL)-1ß, 4, 5, 6, 8, 9, 13, 17, 25 and 33, IFN., CSF1, TSLP, CC16/SCGB1A1 and c-reactive protein).

    Time frame: Comparison of the different arms over the span of 4 months.

  5. Effects of PM2.5 exposures and concentration on lung imaging.

    The lungs will be imaged with hyperpolarized 129Xe gas to measure ventilation defect percent, membrane-to-gas ratio and red blood cell-to-gas ratio. These measures will be standardized and averaged to generate a single composite lung function imaging score per participant.

    Time frame: Comparison of the different arms over the span of 4 months.

  6. Effects of PM2.5 exposures and concentration on circulating brain-derived biomarkers of neuroinflammation.

    Analysis of circulating brain-derived biomarkers of neuroinflammation using the NULISAseq CNS Diesease Panel 120.

    Time frame: Comparison of the different arms over the span of 4 months.

  7. Effects of PM2.5 exposures and concentration on neutrophil extracellular traps (NETs).

    Analysis of counts of neutrophil extracellular traps (NETs).

    Time frame: Comparison of the different arms over the span of 4 months.

  8. Effects of PM2.5 exposures and concentration on host defence proteins.

    Host defense peptides matrix, from e.g. alpha defensin-1, S100A7 and cystatin-SA.

    Time frame: Comparison of the different arms over the span of 4 months.

  9. Effects of PM2.5 exposures and concentration on DNA methylation.

    Measurement of DNA methylation after exposures and determination of epigenetic age.

    Time frame: Comparison of the different arms over the span of 4 months.

  10. Effects of PM2.5 exposures and concentration on glia-derived extracellular vesicles.

    Glia-derived extracellular vesicles will be measured in circulating blood using nanoflow cytometry-based direct labelling.

    Time frame: Comparison of the different arms over the span of 4 months.

Other outcomes

  1. Effects of PM2.5 exposures and concentration on breath volatile organic compounds.

    Collection and analysis of breath volatiles using ReCIVA technology.

    Time frame: Comparison of the different arms over the span of 4 months.

  2. Effects of PM2.5 exposures and concentration on airway microbial taxon abundance.

    The airway microbiome will be characterized using sequencing. Differential abundance analysis will quantify changes in the relative abundance of individual airway microbial taxa across exposure conditions.

    Time frame: Comparison of the different arms over the span of 4 months.

  3. Effects of PM2.5 exposures and concentration on symptoms.

    Symptoms and Perception questionnaires (e.g. https://particleandfibretoxicology.biomedcentral.com/articles/10.1186/s12989-022-00506-6#Sec15) will be completed.

    Time frame: Comparison of the different arms over the span of 4 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2029, 39 months after the start.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 39 months is above that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → May 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2026
First posted
Apr 17, 2026
StartActual
May 26, 2026was Apr 2026
Primary completionEst.
Aug 31, 2029
CompletionEst.
Aug 31, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
1 site added — first site in Canada
Show site
  • Air Pollution Exposure Lab · Vancouver, Canada
Oct 26, 2026
Start date
Apr 1, 2026→May 26, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Canada
    Show site
    • Air Pollution Exposure Lab · Vancouver, Canada
    Start date Apr 1, 2026→May 26, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07536178
Responsible party
Christopher Carlsten (Professor, University of British Columbia) — Principal investigator
First posted
Apr 17, 2026
Start date
May 26, 2026
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

PJ (Parteek) Johal, BCS
Contact
p.johal@ubc.ca
604-875-5132
Agnes Yuen, BSc
Contact
agnes.yuen@ubc.ca
604-875-4111 ext. 66455
Chris Carlsten, MD, MPH
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion